GLP-1
Galapagos NV received a transparency notification from Sands Capital Management, LLC.
Novel target class with dual action in inflammatory disorders
Galapagos NV expands its clinical study program with GLPG1690 in systemic sclerosis, following the recent start of the ISABELA Phase 3 program with ‘1690 in IPF.
Fibrocor Therapeutics L.P. and Galapagos NV announced a global partnership focused on a novel target for idiopathic pulmonary fibrosis (IPF) and other indications.
ADOCIA announced today the first home-use trial to test Adocia’s BioChaperone® Lispro in Beta Bionics autonomous insulin delivery system, the iLetTM.
The battle of the bulge is ongoing and it appears that Americans are losing, according to a report from the U.S. Centers for Disease Control and Prevention. The report shows that Americans are losing height and gaining girth.
Galapagos NV will participate in the 37th Annual J.P. Morgan Healthcare Conference on January 8 & 9, 2019.
Fidelta Ltd is pleased to announce that it has signed an integrated drug discovery agreement with Galapagos based on Fidelta’s macrocyclic platform.
Galapagos NV announced today that the FDA has granted GLPG1972/S201086 Fast Track designation for the treatment of patients with osteoarthritis (OA).
Galapagos NV announces a share capital increase arising from warrant exercises.
PRESS RELEASES